425,000 Shares in Viridian Therapeutics, Inc. (NASDAQ:VRDN) Acquired by Parkman Healthcare Partners LLC

Parkman Healthcare Partners LLC acquired a new stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 425,000 shares of the company's stock, valued at approximately $9,669,000. Viridian Therapeutics makes up approximately 1.2% of Parkman Healthcare Partners LLC's holdings, making the stock its 29th biggest position. Parkman Healthcare Partners LLC owned 0.54% of Viridian Therapeutics as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Quest Partners LLC increased its position in shares of Viridian Therapeutics by 344.0% during the 2nd quarter. Quest Partners LLC now owns 6,056 shares of the company's stock worth $79,000 after purchasing an additional 4,692 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Viridian Therapeutics during the 3rd quarter valued at $149,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Viridian Therapeutics by 24.6% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,961 shares of the company's stock valued at $156,000 after purchasing an additional 2,359 shares in the last quarter. AlphaCentric Advisors LLC increased its stake in shares of Viridian Therapeutics by 108.3% in the second quarter. AlphaCentric Advisors LLC now owns 12,500 shares of the company's stock valued at $163,000 after buying an additional 6,500 shares in the last quarter. Finally, Arizona State Retirement System increased its position in Viridian Therapeutics by 14.7% in the 2nd quarter. Arizona State Retirement System now owns 13,178 shares of the company's stock valued at $171,000 after acquiring an additional 1,688 shares in the last quarter.

Insider Transactions at Viridian Therapeutics

In related news, Director Fairmount Funds Management Llc purchased 1,600,000 shares of Viridian Therapeutics stock in a transaction that occurred on Friday, September 13th. The stock was purchased at an average cost of $18.75 per share, with a total value of $30,000,000.00. Following the completion of the transaction, the director now owns 3,445,813 shares of the company's stock, valued at approximately $64,608,993.75. This trade represents a 86.68 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Thomas W. Beetham acquired 5,000 shares of the business's stock in a transaction dated Friday, September 27th. The stock was bought at an average cost of $23.41 per share, with a total value of $117,050.00. Following the acquisition, the chief operating officer now owns 6,000 shares in the company, valued at $140,460. The trade was a 500.00 % increase in their position. The disclosure for this purchase can be found here. Insiders bought 1,626,400 shares of company stock valued at $30,616,312 over the last three months. Company insiders own 0.65% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on VRDN shares. Royal Bank of Canada restated an "outperform" rating and issued a $44.00 price objective on shares of Viridian Therapeutics in a research report on Thursday, September 19th. The Goldman Sachs Group lifted their target price on shares of Viridian Therapeutics from $25.00 to $31.00 and gave the stock a "buy" rating in a report on Thursday, September 12th. HC Wainwright lifted their target price on shares of Viridian Therapeutics from $27.00 to $34.00 and gave the stock a "buy" rating in a report on Thursday, November 14th. BTIG Research lifted their price objective on Viridian Therapeutics from $56.00 to $61.00 and gave the stock a "buy" rating in a research note on Thursday, September 26th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $38.00 price objective on shares of Viridian Therapeutics in a research note on Monday, November 25th. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $36.33.

Viridian Therapeutics Stock Down 0.6 %

Shares of VRDN traded down $0.13 on Wednesday, hitting $19.96. The company's stock had a trading volume of 1,269,865 shares, compared to its average volume of 1,114,109. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.04. The firm's fifty day moving average price is $22.70 and its 200-day moving average price is $17.54. Viridian Therapeutics, Inc. has a fifty-two week low of $11.40 and a fifty-two week high of $27.20. The firm has a market capitalization of $1.58 billion, a price-to-earnings ratio of -4.63 and a beta of 1.04.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.15) EPS for the quarter, missing analysts' consensus estimates of ($1.11) by ($0.04). The company had revenue of $0.09 million for the quarter, compared to analyst estimates of $0.08 million. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. On average, equities research analysts expect that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.